In order to strengthen its presence in the migraine market, Allergan has agreed to co-promote MAP Pharmaceuticals’ orally inhaled migraine therapy Levadex™ (dihydroergotamine) to neurologists and pain specialists in the US. Levadex has completed Phase III development for acute migraine and is scheduled for regulatory filing in the first half of 2011. MAP will receive US$60 M upfront and up to US$97 M upon meeting certain regulatory milestones associated with the acute migraine indication. Upon approval, Allergan and MAP will share profits equally from US sales to migraine specialists.